Ticagrelor inverse agonist activity at the P2Y


Journal

British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536

Informations de publication

Date de publication:
01 2024
Historique:
revised: 12 05 2023
received: 28 06 2022
accepted: 02 07 2023
medline: 6 12 2023
pubmed: 2 8 2023
entrez: 2 8 2023
Statut: ppublish

Résumé

Ticagrelor is labelled as a reversible, direct-acting platelet P2Y Studies were performed in human platelets, with P2Y Initial studies revealed that a range of P2Y Ticagrelor binding to P2Y

Sections du résumé

BACKGROUND AND PURPOSE
Ticagrelor is labelled as a reversible, direct-acting platelet P2Y
EXPERIMENTAL APPROACH
Studies were performed in human platelets, with P2Y
KEY RESULTS
Initial studies revealed that a range of P2Y
CONCLUSION AND IMPLICATIONS
Ticagrelor binding to P2Y

Identifiants

pubmed: 37530222
doi: 10.1111/bph.16204
doi:

Substances chimiques

Ticagrelor GLH0314RVC
methylthio-ADP 34983-48-7
Diphosphates 0
Adenosine K72T3FS567
Purinergic P2Y Receptor Antagonists 0
Platelet Aggregation Inhibitors 0
Adenosine Diphosphate 61D2G4IYVH
Receptors, Purinergic P2Y12 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

21-35

Subventions

Organisme : British Heart Foundation
ID : PG/17/62/33190
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/20/1/34617
Pays : United Kingdom

Informations de copyright

© 2023 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Références

Front Pharmacol. 2019 Mar 18;10:209
pubmed: 30936830
Nat Methods. 2005 Mar;2(3):177-84
pubmed: 15782186
Platelets. 2015;26(4):324-30
pubmed: 25905916
J Thromb Haemost. 2017 May;15(5):858-867
pubmed: 28092426
J Thromb Haemost. 2021 Jul;19(7):1800-1812
pubmed: 33834609
J Thromb Haemost. 2009 Sep;7(9):1556-65
pubmed: 19552634
Cell Mol Life Sci. 2019 Feb;76(3):561-576
pubmed: 30406277
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Transfusion. 2019 May;59(5):1850-1856
pubmed: 30802336
Nature. 2014 May 1;509(7498):115-8
pubmed: 24670650
Br J Pharmacol. 2000 May;130(1):1-12
pubmed: 10780991
J Thromb Haemost. 2011 Sep;9(9):1730-7
pubmed: 21707911
Am Heart J. 2009 Apr;157(4):599-605
pubmed: 19332184
Thromb Haemost. 2019 Oct;119(10):1606-1616
pubmed: 31408901
Clin Res Cardiol. 2017 Nov;106(11):868-874
pubmed: 28653184
J Comput Aided Mol Des. 2015 Aug;29(8):737-56
pubmed: 26194851
Blood. 2005 May 1;105(9):3552-60
pubmed: 15665114
Br J Clin Pharmacol. 2010 Jul;70(1):65-77
pubmed: 20642549
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Eur Heart J. 2014 Jun 14;35(23):1510-4
pubmed: 24748565
Blood. 2015 May 28;125(22):3484-90
pubmed: 25788700
N Engl J Med. 2015 Jan 8;372(2):196-7
pubmed: 25564918
J Am Coll Cardiol. 2014 Apr 22;63(15):1500-9
pubmed: 24333493
Br J Pharmacol. 2024 Jan;181(1):21-35
pubmed: 37530222
N Engl J Med. 2007 Nov 15;357(20):2001-15
pubmed: 17982182
N Engl J Med. 2019 May 9;380(19):1825-1833
pubmed: 30883047
J Thromb Haemost. 2012 Apr;10(4):521-8
pubmed: 22268852
Ann Transl Med. 2019 Sep;7(17):410
pubmed: 31660309
J Thromb Haemost. 2014 Nov;12(11):1898-905
pubmed: 25186974
Br J Pharmacol. 2021 Oct;178 Suppl 1:S27-S156
pubmed: 34529832
Circulation. 2009 Dec 22;120(25):2577-85
pubmed: 19923168
Sci Rep. 2018 Jul 17;8(1):10804
pubmed: 30018317
Blood Adv. 2021 Apr 13;5(7):1884-1898
pubmed: 33792632
Clin Toxicol (Phila). 2018 Dec;56(12):1200-1203
pubmed: 29889575
Blood. 2016 Dec 8;128(23):2717-2728
pubmed: 27694321
Br J Pharmacol. 2022 Aug;179(15):3907-3913
pubmed: 35673806
N Engl J Med. 2015 May 7;372(19):1791-800
pubmed: 25773268
Nature. 2014 May 1;509(7498):119-22
pubmed: 24784220

Auteurs

Jawad Khalil (J)

School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.

Tudor Dimofte (T)

School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.

Timothy Roberts (T)

School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.

Michael Keith (M)

School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.

Kumuthu Amaradasa (K)

School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.

Matthew S Hindle (MS)

Leeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds, UK.

Sukhinder Bancroft (S)

School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.

James L Hutchinson (JL)

School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.

Khalid Naseem (K)

Leeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds, UK.

Thomas Johnson (T)

Bristol Medical School, University of Bristol, Bristol, UK.

Stuart J Mundell (SJ)

School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH